Table 1 –
Clinicopathologic details of study cohort automatically extracted from electronic health record
| Patient Demographics | Study cohort (n=516) | % |
|---|---|---|
|
| ||
| Male gender | 296 | 57.40% |
|
| ||
| Race | ||
|
| ||
| White or Caucasian | 400 | 77.50% |
| Black or African American | 36 | 7.00% |
| Asian | 30 | 5.80% |
| American Indian or Alaska Native | 2 | 0.40% |
| Other | 45 | 8.70% |
| Declined to Answer | 3 | 0.60% |
|
| ||
| Ethnicity | ||
|
| ||
| Not Hispanic or Latino | 427 | 82.70% |
| Hispanic or Latino | 84 | 16.30% |
| Declined to Answer | 5 | 1.00% |
|
| ||
| Age at diagnosis | 56 (17–92) | |
|
| ||
|
| ||
| MRI Data | ||
|
| ||
| T category | ||
|
| ||
| T0 | 4 | 0.80% |
| T1 | 2 | 0.40% |
| T2 | 126 | 24.40% |
| T2/T3 | 21 | 4.10% |
| T3 | 274 | 53.00% |
| T4 | 79 | 15.30% |
| Tx | 10 | 2.00% |
|
| ||
| N category | ||
|
| ||
| N0 | 87 | 16.90% |
| N+ | 302 | 58.50% |
| Nx | 127 | 24.60% |
|
| ||
| Extramural vascular invasion | 164 | 31.80% |
|
| ||
| Pelvic sidewall adenopathy | 69 | 13.40% |
|
| ||
| Mesorectal fascia involvement | 155 | 30.10% |
|
| ||
| Anal sphincter involvement | 63 | 12.20% |
|
| ||
| Distance from anal verge (cm) | 7 (0–29) | |
|
| ||
|
| ||
| CT Data | ||
|
| ||
| Stage IV at diagnosis | ||
|
| ||
| 0 | 413 | 80.00% |
| a | 66 | 12.80% |
| b | 4 | 0.80% |
| c | 2 | 0.40% |
| Missing | 31 | 6.00% |
|
| ||
| Liver metastases at diagnosis | 33 | 6.40% |
|
| ||
| Lung metastases at diagnosis | 40 | 7.80% |
|
| ||
| Distant lymph node metastases at diagnosis | 1 | 0.20% |
|
| ||
| Peritoneal metastases at diagnosis | 2 | 0.40% |
|
| ||
|
| ||
| Mutational Data | ||
|
| ||
| KRAS | ||
|
| ||
| Wildtype | 93 | 18.00% |
| Mutation | 58 | 11.20% |
| Not-tested | 365 | 70.80% |
|
| ||
| BRAF | ||
|
| ||
| Wildtype | 142 | 27.50% |
| Mutation | 10 | 1.90% |
| Not-tested | 364 | 70.60% |
|
| ||
| TP53 | ||
|
| ||
| Wildtype | 44 | 8.50% |
| Mutation | 96 | 18.60% |
| Not-tested | 376 | 72.90% |
|
| ||
| PTEN | ||
|
| ||
| Wildtype | 132 | 25.50% |
| Mutation | 8 | 1.60% |
| Not-tested | 376 | 72.90% |
|
| ||
| FBXW7 | ||
|
| ||
| Wildtype | 114 | 22.10% |
| Mutation | 26 | 5.00% |
| Not-tested | 376 | 72.90% |
|
| ||
| SMAD4 | ||
|
| ||
| Wildtype | 125 | 24.20% |
| Mutation | 14 | 2.70% |
| Not-tested | 377 | 73.10% |
|
| ||
| PIK3CA | ||
|
| ||
| Wildtype | 130 | 25.20% |
| Mutation | 17 | 3.30% |
| Not-tested | 369 | 71.50% |
|
| ||
| BRCA2 | ||
|
| ||
| Wildtype | 128 | 24.80% |
| Mutation | 6 | 1.20% |
| Not-tested | 382 | 74.00% |
|
| ||
| ARID1A | ||
|
| ||
| Wildtype | 115 | 22.30% |
| Mutation | 6 | 1.20% |
| Not-tested | 390 | 76.60% |
|
| ||
| NOTCH1 | ||
|
| ||
| Wildtype | 136 | 26.40% |
| Mutation | 4 | 0.80% |
| Not-tested | 376 | 72.80% |
|
| ||
| NOTCH3 | ||
|
| ||
| Wildtype | 78 | 15.10% |
| Mutation | 2 | 0.40% |
| Not-tested | 436 | 84.50% |
|
| ||
| ATM | ||
|
| ||
| Wildtype | 130 | 25.20% |
| Mutation | 8 | 1.60% |
| Not-tested | 378 | 73.20% |
|
| ||
| NRAS | ||
|
| ||
| Wildtype | 144 | 27.80% |
| Mutation | 6 | 1.20% |
| Not-tested | 366 | 71.00% |
|
| ||
| ERBB2 | ||
|
| ||
| Wildtype | 132 | 25.60% |
| Mutation | 7 | 1.40% |
| Not-tested | 377 | 73.00% |
|
| ||
| KIT | ||
|
| ||
| Wildtype | 139 | 27.00% |
| Mutation | 0 | 0% |
| Not-tested | 377 | 73.00% |
|
| ||
| EGFR | ||
|
| ||
| Wildtype | 138 | 26.80% |
| Mutation | 1 | 0.20% |
| Not-tested | 377 | 73.00% |
|
| ||
|
| ||
| Preoperative Therapy | ||
|
| ||
| Preoperative regimen | ||
|
| ||
| Conventional chemoradiation | 147 | 28.50% |
| Total Neoadjuvant Therapy | 185 | 35.90% |
| Chemotherapy only | 30 | 5.80% |
| Radiation therapy only | 10 | 1.90% |
| Other regimen | 5 | 1.00% |
| No neoadjuvant | 139 | 26.90% |
|
| ||
| Preoperative chemotherapy | ||
|
| ||
| FOLFOX | 95 | |
| FOLFOX+BEVACIZUMAB | 10 | |
| FOLFOX, CAPECITABINE | 51 | |
| FOLFOXIRI | 16 | |
| FOLFOXIRI, CAPECITABINE | 5 | |
| FOLFOXIRI, BEVACIZUMAB | 4 | |
| XELOX | 12 | |
| Other | 27 | |
|
| ||
| Preoperative radiation | ||
|
| ||
| Long course chemoradiation | 230 | 44.60% |
| Short course radiation | 112 | 21.70% |
|
| ||
|
| ||
| Pathology Data | ||
|
| ||
| pT | ||
|
| ||
| pT0 | 34 | 6.60% |
| pT1 | 57 | 11.00% |
| pT2 | 114 | 22.10% |
| pT3 | 268 | 51.90% |
| pT4 | 39 | 7.60% |
| pTx | 1 | 0.20% |
| Missing | 3 | 0.60% |
|
| ||
| pN | ||
|
| ||
| pN0 | 312 | 60.50% |
| pN1 | 131 | 25.40% |
| pN2 | 61 | 11.80% |
| pNx | 9 | 1.70% |
| Missing | 3 | 0.60% |
|
| ||
| Grade | ||
|
| ||
| 1 | 7 | 1.40% |
| 2 | 448 | 86.80% |
| 3 | 57 | 11.00% |
| x | 2 | 0.40% |
| Missing | 2 | 0.40% |
|
| ||
| Lymphovascular invasion | 228 | 44.20% |
|
| ||
| Perineural invasion | 187 | 36.20% |
|
| ||
| Negative margins | 510 | 98.80% |
|
| ||
| Status of mesorectal excision | ||
|
| ||
| Complete | 139 | 26.90% |
| Incomplete | 15 | 2.90% |
| Nearly complete | 59 | 11.50% |
| Missing | 303 | 58.70% |
|
| ||
| Tumor Regression Grade | ||
|
| ||
| 0 | 36 | 7.00% |
| 1 | 70 | 13.60% |
| 2 | 200 | 38.80% |
| 3 | 62 | 12.00% |
| NA | 148 | 28.70% |
|
| ||
|
| ||
| Follow-up | ||
|
| ||
| Recurrence | 27 | 5.20% |
|
| ||
| Time to recurrence (days; median, range) | 777 (93–2410) | |
|
| ||
| Death | 22 | 4.30% |